Skip to content

Mescaline: all studies

Page 68 of 97: studies 671 to 680 of 963, newest first. Back to the mescaline overview

Research

Psychedelic medicines

Australian Journal of Chemistry July 16, 2023 Matthew Piggott, Peter J. Duggan 1 citation

The recent heightened public enthusiasm for the potential therapeutic benefits of psychedelics, especially for treatment-resistant mental health conditions, has resulted in a renewed interest in the underlying science that governs their properties and pharmacology.The science of psychedelics is an intriguing, multi-disciplinary field and encompasses many known psychedelic substances, including...

Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review

Advances in Mental Health July 13, 2023 Jorge Valdiviezo‐oña, Lizbeth Toscano-Molina, Juan Fernando Chávez et al. 4 citations

Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) and their outcomes.Method To be included, peer-reviewed articles had to be written in English or Spanish and had to address the usage of psychedelics by people reporting an ED. Searches were conducted on PubMed, Scopus, and Web of Science. Data on key...

Food of the Gods?

July 7, 2023 Neil Carrier, Lisa L. Gezon

This chapter focuses on drugs in spiritual and religions contexts, considering their role in altered states of consciousness, divination and healing. The first part of the chapter presents the sub-discipline of ethnobotany and its contribution to anthropological ideas about hallucinogenic plant substances and their wider connection of drugs to shamanism and the spirit world. It also discusses...

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Journal of Psychopharmacology July 1, 2023 Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred et al. 52 citations

Background: The classical psychedelics, psilocybin, peyote, ayahuasca/ N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promising new treatments for psychiatric illnesses, such as depression, anxiety, addiction, and obsessive-compulsive disorders. However, their profound and characteristic subjective effects raise concern for distinctive biases in randomized clinical...

DOI: 10.1177/02698811231180276 (opens in new tab) Randomized controlled trial Clinical trial Medline Clinical psychology

MDMA and the Military

The History of MDMA June 29, 2023 Torsten Passie

Abstract In the 1920s, physicians discovered the potential for ‘speech induction’ offered by psychoactive substances. The German Nazis were the first to conduct experiments on the use of ‘truth drugs’ for interrogation purposes. Later, after some American prisoners of war ‘confessed’ to the use of biological weapons in the Korean war, the United States (US) Army suspected that they had been...

The Research of Alexander T. Shulgin

The History of MDMA June 29, 2023 Torsten Passie

Abstract The American chemist Alexander T. Shulgin played a significant role in the ‘rediscovery’ of MDMA in the 1970s. In 1960, an experience with mescaline inspired Shulgin to undertake research with psychoactive drugs. He subsequently synthesized psychoactive chemicals and tested them on himself and a group of others. In the early 1960s, Shulgin studied the chemistry of nutmeg: chemical...

Henri Michaux's program for the psychedelic humanities

Frontiers in Psychology May 16, 2023 Oliver Davis 4 citations

This article presents an analytical reading of the extraordinarily rich cultural production around drugs by the 20th-century French poet, writer, critic, and visual artist Michaux (1899–1984). Over about a decade, from the mid-1950's, the otherwise habitually sober Michaux wrote five books, included within which were dozens of drawings, and made one half-hour film, charting his adventures as an...

Microbiome–Gut–Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders

ACS Medicinal Chemistry Letters May 11, 2023 Robert B. Kargbo 15 citations

The gut-brain axis (GBA) refers to the sophisticated bidirectional communication system connecting the digestive system with the central nervous system. This interaction is enabled by a series of intricate signaling processes, encompassing various neuro-immune and hormonal pathways. The association between the gut microbiome and mental health has garnered immense scientific and public interest,...

DOI: 10.1021/acsmedchemlett.3c00168 (opens in new tab) Full text (opens in new tab) Gut–brain axis Gut microbiome Lysergic acid Enteric nervous system +1

Incidence of Intoxications in the Emergency Department of Galati Hospital with Examples of Cardiovascular Effects of MDMA Intoxication

Diagnostics March 10, 2023 Liliana Dragomir, Virginia Marina, Mihaela Anghele et al.

MDMA (3,4-methylenedioxymethamphetamine; commonly referred to as “Molly” or “ecstasy”) is a synthetic compound, structurally and pharmacologically similar to both amphetamines and mescaline. MDMA differs somewhat from traditional amphetamines in that it is not structurally similar to serotonin. Cocaine is rare and cannabis is consumed less frequently than in Western Europe. Heroin is the drug...

DOI: 10.3390/diagnostics13050940 (opens in new tab) Full text (opens in new tab) Methylen-dioxy-methamphetamine Intoxication Serotonin drug

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample

Scientific Reports February 11, 2023 Grant Jones, Joshua Lipson, Erica Wang 2 citations

Abstract Impairment in social functioning is a common source of morbidity across many mental health disorders, yet there is a dearth of effective and easily implemented interventions to support social functioning. MDMA/ecstasy and classic psychedelics (psilocybin, LSD, peyote, mescaline) represent two potential treatments for impairments in social functioning, as evidence suggests these...